Direct acting oral anticoagulants versus low molecular weight heparin for primary thromboprophylaxis in cancer patients
INTRODUCTION: Low molecular weight heparin is currently the standard therapy for the primary prevention of thromboembolic disease in cancer patients. The use of direct-acting anticoagulants could be an alternative, but its efficacy and safety profile in these types of patients remains unclear.
METHODS: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple sources of information, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from identified reviews, analyzed data from primary studies, performed a meta-analysis, and prepared a summary table of results using the GRADE method.
RESULTS AND CONCLUSIONS: We identified four systematic reviews that together included two primary studies, of which both correspond to trials. We conclude that the use of direct-acting oral anticoagulants probably increases the outcome of major bleeding and likely slightly increases the risk of thromboembolic disease. No studies were found that evaluated the outcome of quality of life or mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Medwave - 21(2021), 4 vom: 03. Mai, Seite e8178 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Anticoagulantes orales de acción directa versus heparina de bajo peso molecular para tromboprofilaxis primaria en pacientes con cáncer |
|---|
| Beteiligte Personen: |
Méndez, Natalia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 25.10.2021 Date Revised 23.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5867/medwave.2021.04.8178 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325865523 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325865523 | ||
| 003 | DE-627 | ||
| 005 | 20231225193342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.5867/medwave.2021.04.8178 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325865523 | ||
| 035 | |a (NLM)34037582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Méndez, Natalia |e verfasserin |0 (orcid)0000-0001-9912-8829 |4 aut | |
| 245 | 1 | 0 | |a Direct acting oral anticoagulants versus low molecular weight heparin for primary thromboprophylaxis in cancer patients |
| 246 | 3 | 3 | |a Anticoagulantes orales de acción directa versus heparina de bajo peso molecular para tromboprofilaxis primaria en pacientes con cáncer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2021 | ||
| 500 | |a Date Revised 23.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Low molecular weight heparin is currently the standard therapy for the primary prevention of thromboembolic disease in cancer patients. The use of direct-acting anticoagulants could be an alternative, but its efficacy and safety profile in these types of patients remains unclear | ||
| 520 | |a METHODS: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple sources of information, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from identified reviews, analyzed data from primary studies, performed a meta-analysis, and prepared a summary table of results using the GRADE method | ||
| 520 | |a RESULTS AND CONCLUSIONS: We identified four systematic reviews that together included two primary studies, of which both correspond to trials. We conclude that the use of direct-acting oral anticoagulants probably increases the outcome of major bleeding and likely slightly increases the risk of thromboembolic disease. No studies were found that evaluated the outcome of quality of life or mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Epistemonikos | |
| 650 | 4 | |a GRADE | |
| 650 | 4 | |a Low molecular weight heparin | |
| 650 | 4 | |a Thromboembolic disease | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a Direct oral anticoagulants | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 700 | 1 | |a Norambuena, Constanza |e verfasserin |0 (orcid)0000-0002-7561-9524 |4 aut | |
| 700 | 1 | |a Silva, Symón |e verfasserin |0 (orcid)0000-0003-2566-4893 |4 aut | |
| 700 | 1 | |a López, Valentín |e verfasserin |0 (orcid)0000-0003-1323-7843 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medwave |d 2014 |g 21(2021), 4 vom: 03. Mai, Seite e8178 |w (DE-627)NLM241622328 |x 0717-6384 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:4 |g day:03 |g month:05 |g pages:e8178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5867/medwave.2021.04.8178 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 4 |b 03 |c 05 |h e8178 | ||